The Oncology Brothers, Drs. Rohit Gosain and Rahul Gosain, speak with Cathy Eng, MD, of the Vanderbilt-Ingram Cancer Center, about treatment of metastatic colorectal cancer (CRC). She shared data from the FRESCO-2 trial of fruquintinib versus placebo in patients with metastatic CRC. The study observed an overall survival improvement of 2.6 months and progression-free survival improvement of 1.9 months for patients treated with fruquintinib versus placebo. The study was conducted in a very heavily pretreated population, with patients having received a median of 5 prior lines of therapy.
“I feel very confident that if you move [fruquintinib] to an earlier setting, not necessarily the fifth-line setting, you’re probably going to see a significant benefit for the patient,” she told Drs Rohit Gosain and Rahul Gosain. “I look forward to seeing some additional data [of fruquintinib] in combination.”
Fruquintinib is approved for use in China and is under review for approval in the United States.